(Q40070152)

English

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma (English)

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ahmed FY

1

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Leonard GA

2

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

A'Hern R

3

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Taylor AE

4

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Lorentzos A

5

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Atkinson H

6

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Moore J

7

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Nicolson MC

8

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Riches PG

9

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Gore ME

10

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

language of work or name

0 references

publication date

1 October 1996

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

74

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

7

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

1109-1113

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1996.498

0 references

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

22 September 2017

The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

22 September 2017

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

22 September 2017

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

25 September 2017

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

25 September 2017

The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

15 June 2018

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

15 June 2018

Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

15 June 2018

Seasonal changes in 24-h and basal energy expenditures in rural Gambian men as measured in a respiration chamber

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

20 August 2018

Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077131

20 August 2018

Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/8855983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8855983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/8855983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Malignant melanoma and renal cell carcinoma: Immunological and haematological effects of recombinant human interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8855983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8855983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1996.498

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40070152&oldid=1883614081"